tiprankstipranks

Valneva granted marketing authorization for Ixchiq in Brail

Valneva (VALN) announced that the Brazilian Health Regulatory Agency has granted marketing authorization to its single-dose vaccine Ixchiq for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The decision marks the world’s first approval of a chikungunya vaccine in an endemic country, the company said in a statement. ANVISA continues to review VLA1555, the chikungunya vaccine candidate which, if approved, will be locally manufactured and distributed by Instituto Butantan pursuant to its collaboration with Valneva. Potential approval is anticipated in mid-2025.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue